After having recently met with SI-Bone management, including CEO Laura Francis and CFO Anshul Maheshwari, Jefferies said the meetings were positive in tone with good updates on trends and momentum. The firm, which reiterates its Buy rating and $30 price target, would be buyers of SI-Bone shares at current levels, citing the company’s differentiated portfolio backed by level 1 clinical data, dominant market position and new products.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SIBN:
- SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024
- SI-Bone price target lowered to $24 from $26 at Truist
- SI-Bone sees FY24 revenue $162M-165M, consensus $159.06M
- SI-Bone reports Q4 EPS (27c), consensus (28c)
- SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance
